NCT02880371 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02880371
Title	A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors
Recruitment	Terminated
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Array BioPharma
Indications	melanoma stomach cancer colorectal cancer triple-receptor negative breast cancer lung non-small cell carcinoma urinary bladder cancer head and neck squamous cell carcinoma ovarian cancer pancreatic ductal adenocarcinoma
Therapies	ARRY-382 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

NCT02880371
Clinical Trial Detail